Tenax Therapeutics, Inc. (TENX)
NASDAQ: TENX · Real-Time Price · USD
14.60
-0.51 (-3.38%)
At close: Apr 28, 2026, 4:00 PM EDT
14.88
+0.28 (1.92%)
After-hours: Apr 28, 2026, 4:56 PM EDT
Tenax Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Tenax Therapeutics stock have an average target of 29.67, with a low estimate of 20 and a high estimate of 35. The average target predicts an increase of 103.22% from the current stock price of 14.60.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 17, 2026.
Analyst Ratings
The average analyst rating for Tenax Therapeutics stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 3 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 2 | 2 | 2 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $35 | Buy | Initiates | $35 | +139.73% | Mar 17, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $25 → $34 | Strong Buy | Maintains | $25 → $34 | +132.88% | Mar 16, 2026 |
| Guggenheim | Guggenheim | Strong Buy Maintains $14 → $25 | Strong Buy | Maintains | $14 → $25 | +71.23% | Dec 17, 2025 |
| Piper Sandler | Piper Sandler | Buy Initiates $20 | Buy | Initiates | $20 | +36.99% | Sep 8, 2025 |
| Guggenheim | Guggenheim | Strong Buy Maintains $15 → $14 | Strong Buy | Maintains | $15 → $14 | -4.11% | Aug 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.59
from -1.34
EPS Next Year
-1.49
from -1.59
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||||
| Avg | n/a | n/a | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.43 | -1.33 | ||||||
| Avg | -1.59 | -1.49 | ||||||
| Low | -1.79 | -1.78 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.